Severe Misconduct, Repeat Offending And Underreporting: UK/EU Codes Come Under Fire

Listen to this article

The UK and EU pharma industry associations have defended their respective codes of practice despite alarming study results. Meanwhile, a consultation on proposals to revise the UK code received over 3,500 comments.

A study has cast doubt on the effectiveness of self-regulatory codes of practice • Source: Shutterstock

The Association of the British Pharmaceutical Industry is standing by its code of practice after a study found that self-regulation in the UK was ineffective in preventing company misconduct, with the situation being even worse in most other parts of Europe.

Key Takeaways

A study of self-regulation in the UK and the ABPI’s code of practice has found evidence of persistent and often severe misconduct by companies in the UK.

"We believe that UK self-regulation works,” the ABPI’s Amit Aggarwal said of the study, which found evidence of “persistent and...

India And Pakistan Boost Transparency In Industry-Doctor Interactions

Sep 12 2024

• By Vibha Sharma

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.

Celebs Bring Extra Scrutiny To Advertisements, US FDA Tells AbbVie

Sep 11 2024

• By Sarah Karlin-Smith

AbbVie’s migraine ad overstates the drug’s benefit, a problem that is amplified by using a celebrity, the agency says.

Misconstruing Single-Arm Study Data Lands BMS In Trouble With US FDA

Aug 08 2024

• By Sarah Karlin-Smith

The lung cancer drug Krazati from Bristol Myers Squibb’s Mirati Therapeutics drew an FDA ad/promo untitled letter, highlighting the agency's trend of pursuing false or misleading efficacy claims, particularly when data comes from outside approved labeling.